Hemolytic Disease of the Newborn: A Review of Current Trends and Prospects

Akshay Kiran Myle, Ghanim Hamid Al-Khattabi, Akshay Kiran Myle, Ghanim Hamid Al-Khattabi

Abstract

Hemolytic disease of the newborn (HDN), also known as Erythroblastosis fetalis, is a hemolytic condition that predominantly affects rhesus-positive fetuses and infants born to rhesus-negative mothers. The pathophysiology of HDN begins with maternal antibodies attacking fetal red blood cells following alloimmunization due to rhesus or ABO incompatibility between the maternal and fetal blood. Previously, HDN was known to cause fetal death in 1% of all pregnancies, but with the advent of immunoprophylactic therapies, the condition can be currently fairly well managed with fewer complications if diagnosed early. Diagnosis calls for extensive history taking, physical examination, serological studies, and imaging modalities such as pelvic ultrasound scans. To prevent the disease, earlier intravenous immunoglobulin (IVIG) should be given to pregnant Rh- women who have not been sensitized. It is also vital to understand prospective complications such as severe hyperbilirubinemia and develop appropriate remedies. Because of its great incidence and nature, HDN has been thoroughly explored, and more studies are being conducted each year, revealing new insights about the condition. This review covers the disorder's etiology, diagnosis, and management, including the most current findings as of 2021, as well as trends and prospects, to help in future research and evidence-based medical practice.

Keywords: alloimmunization; fetomaternal hemorrhage; hemolysis; immunoprophylaxis.

Conflict of interest statement

The authors report no conflicts of interest in this work.

© 2021 Myle and Al-Khattabi.

References

    1. Jackson ME, Baker JM. Hemolytic disease of the fetus and newborn: historical and current state. Clin Lab Med. 2021;41(1):133–151. doi:10.1016/j.cll.2020.10.009
    1. Gupta GK, Balbuena-Merle R, Hendrickso JE, Tormey CA. Immunohematologic aspects of alloimmunization and alloantibody detection: a focus on pregnancy and hemolytic disease of the fetus and newborn. Transfus Apheresis Sci. 2020;10:102946.
    1. Alaqeel AA. Hyporegenerative anemia and other complications of rhesus hemolytic disease: to treat or not to treat is the question. Pan Afr Med J. 2019;32:134.
    1. Routray SS, Behera R, Mallick B, et al. The spectrum of hemolytic disease of the newborn: evaluating the etiology of unconjugated hyperbilirubinemia among neonates pertinent to immunohematological workup. Cureus. 2021;13(8):110.
    1. Doll P. Hemolytic disease of newborn: symptom and causes. Pediatrics. 2021;132(3):e145–e232. doi:10.2342/peds.114.2.e143
    1. Cowan H. The discovery of human blood groups: Karl Otto Landsteiner. Br J Cardiac Nursing. 2017;12(6):290–292. doi:10.12968/bjca.2017.12.6.290
    1. Akkök ÇA, Seghatchian J. Immunohematologic issues in ABO-incompatible allogeneic hematopoietic stem cell transplantation. Transfus Apheresis Sci. 2018;57(6):812–815. doi:10.1016/j.transci.2018.10.020
    1. Wang R, Li Y, Tong Y, Su N. Hemolytic disease of the fetus and newborn caused by anti-group A IgG from a group B mother. J Pediatr Hematol Oncol. 2021;43(6):e785–e787. doi:10.1097/MPH.0000000000001948
    1. Ree IM, Smits-Wintjens VE, van der Bom JG, van Klink JM, Oepkes D, Lopriore E. Neonatal management and outcome in alloimmune hemolytic disease. Expert Rev Hematol. 2017;10(7):607–616. doi:10.1080/17474086.2017.1331124
    1. Basu S, Kaur R, Kaur G. Hemolytic disease of the fetus and newborn: current trends and perspectives. Asian J Transfus Sci. 2011;5(1):3. doi:10.4103/0973-6247.75963
    1. Kurian R. To Study the Prevalence of ABO Incompatibility in O Blood Group Mothers and Assessment of IgG Subclasses (IgG1 and IgG3) in them and its Correlation with Occurrence and Severity of ABO Hemolytic Disease of Newborn (ABO-HDN) in a Tertiary Health Care Centre in South India [Doctoral dissertation]. Vellore: Christian Medical College; 2020
    1. Tao E, Ye D, Long G, et al. Severe neonatal anemia affected by massive fetomaternal hemorrhage: a single-center retrospective observational study. J Maternal-Fetal Neonatal Med. 2020;1–7. doi:10.1080/14767058.2020.1845313
    1. Zwiers C, Scheffer‐Rath ME, Lopriore E, de Haas M, Liley HG. Immunoglobulin for alloimmune hemolytic disease in neonates. Cochrane Database Syst Rev. 2018;2018(3):e235. doi:10.1002/14651858.CD003313.pub2
    1. Calhoun DA, Mahoney DH Jr. Postnatal diagnosis and management of hemolytic disease of the fetus and newborn; 2018.
    1. Pichon JBL, Riordan SM, Watchko J, Shapiro SM. The neurological sequelae of neonatal hyperbilirubinemia: definitions, diagnosis, and treatment of the kernicterus spectrum disorders (KSDs). Curr Pediatr Rev. 2017;13(3):199–209.
    1. Watchko JF. Neonatal indirect hyperbilirubinemia and kernicterus. In: Christine A. Gleason and Sandra E. Juul, editor, Avery’s Diseases of the Newborn. Elsevier; 2018:1198–1218.
    1. Usman F, Diala UM, Shapiro S, LePichon JB, Slusher TM. Acute bilirubin encephalopathy and its progression to kernicterus: current perspectives. Res Rep Neonatol. 2018;8:33. doi:10.2147/RRN.S125758
    1. Akorsu EE, Acquaye JK, Benneh AA, Oppong SA, Olayemi E. Fetomaternal hemorrhage among pregnant women in Accra, Ghana. Int J Gynecol Obstet. 2019;146(3):333–338. doi:10.1002/ijgo.12890
    1. Hall V, Avulakunta ID. Hemolytic Diseases of the Newborn. StatPearls [Internet]; 2021.
    1. Adam DL, Bowes L, Goodyear L, Moorehead PC. Conservative management of hyperferritinemia in the fetus and newborn hemolytic disease: a case report and review of the literature. J Pediatr Hematol Oncol. 2021;43(2):73–76. doi:10.1097/MPH.0000000000001586
    1. Kumawat V, Kulkarni K, Goyal M, Lokadas V. ABO hemolytic disease of the fetus and newborn; still a diagnostic dilemma: a case report. Indian J Hematol Blood Transfus. 2018;34(1):183–184. doi:10.1007/s12288-017-0792-1
    1. Jain A, Malhotra S, Marwaha N, Kumar P, Sharma RR. Severe ABO hemolytic disease of fetus and newborn requiring blood exchange transfusion. Asian J Transfus Sci. 2018;12(2):176. doi:10.4103/ajts.AJTS_106_17
    1. Subramaniyan R. Blocked D in RhD hemolytic disease of fetus and newborn. Global J Transfus Med. 2019;4(1):114.
    1. Haider M, Memon S, Tariq F, Fatima S, Hameed A. Rhesus isoimmunization: late-onset hemolytic disease of the newborn without jaundice. Cureus. 2020;12(1):111.
    1. Ajmani PS. Hemolytic disease of the newborn. In: Immunohematology and Blood Banking. Singapore: Springer; 2020:103–117.
    1. Bi SH, Jiang LL, Dai LY, et al. Rh-incompatible hemolytic disease of the newborn in Hefei. World J Clin Cases. 2019;7(20):3202. doi:10.12998/wjcc.v7.i20.3202
    1. Singh R, Garg P, Sucheta KA, Babra M. Comparison between conventional tube method and gel card technique for blood cross-matching: a study in a tertiary care center of north India. Int J Res Pharm Sci. 2020;11(4):6500–6503. doi:10.26452/ijrps.v11i4.3529
    1. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol. 2002;100(3):600–611. doi:10.1016/s0029-7844(02)02180-4
    1. Al-Lawama M, Badran E, Ala’Elrimawi ABM, Alkhatib H. Intravenous Immunoglobulins as adjunct treatment to phototherapy in isoimmune hemolytic disease of the newborn: a retrospective case-control study. J Clin Med Res. 2019;11(11):760.
    1. Pan J, Zhan C, Yuan T, et al. Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study. J Perinatol. 2021;4:1–6.
    1. AlKhater SA, Albalwi RA, Alomar SA, et al. Value of the direct antiglobulin test in predicting the need for phototherapy in newborns. J Blood Med. 2021;12:53. doi:10.2147/JBM.S291606
    1. Krog GR, Donneborg ML, Hansen BM, et al. Prediction of ABO hemolytic disease of the newborn using pre-and perinatal quantification of maternal anti-A/anti-B IgG titer. Pediatr Res. 2020;15:1–8.
    1. Tewari VV, Kumar A, Singhal A, et al. Evaluation of Rh-hemolytic disease in neonates and management with early intensive phototherapy in the neonatal intensive care unit. J Trop Pediatr. 2020;66(1):75–84.
    1. Metcalf RA, Khan J, Andrews J, Mayock D, Billimoria Z, Pagano MB. Severe ABO hemolytic disease of the newborn requiring exchange transfusion. J Pediatr Hematol Oncol. 2019;41(8):632–634. doi:10.1097/MPH.0000000000001248
    1. El Fekey SWI, El-Sharkawy HM, Ahmed AAEE, Nassar MAE, Elgendy MM. Effect of intravenous immunoglobulin in reducing bilirubin levels in hemolytic disease of newborn. Egypt J Hospital Med. 2019;74(5):957–968. doi:10.21608/ejhm.2019.25779
    1. Mimura K, Endo M, Takahashi A, et al. Successful management of fetal hemolytic disease due to strong anti-Rh17 with plasma exchange and intrauterine transfusion in a woman with the D−− phenotype. Int J Hematol. 2020;111(1):149–154. doi:10.1007/s12185-019-02735-6
    1. Steiner LA, Bizzarro MJ, Ehrenkranz RA, Gallagher PG. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics. 2007;120(1):27–32. doi:10.1542/peds.2006-2910
    1. Venkataraman R, Yusuf K. Intravenous immunoglobulin in the management of a rare cause of hemolytic disease of the newborn: anti-SARA antibodies. J Neonatal Perinatal Med. 2017;10(3):329–332. doi:10.3233/NPM-16131
    1. Maisonneuve E, Toly-Ndour C, Jouannic JM. Postponing early intrauterine transfusion with intravenous immunoglobulin treatment: the PETIT study on the severe hemolytic disease of the fetus and newborn. Am J Obstet Gynecol. 2019;220(3):288. doi:10.1016/j.ajog.2018.10.025
    1. Hughes GO, Osman J, Coady AM, Klonin H. Acute hemoglobin increase after transfusion and immunoglobulin for rhesus hemolytic disease of the newborn. J Clin Neonatol. 2018;7(1):48. doi:10.4103/jcn.JCN_48_17
    1. Mark A, Foster AM, Grossman D, et al. Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation’s Clinical Policies Committee. Contraception. 2019;99(5):265–266. doi:10.1016/j.contraception.2019.02.008
    1. de Haas M, Thurik FF, van der Ploeg CP, et al. Sensitivity of fetal RhD screening for safe guidance of targeted anti–D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands. Obstet Gynecol Surv. 2017;72(3):155–157. doi:10.1097/
    1. Sahoo T, Thukral A, Sankar MJ. Delayed cord clamping in Rh-alloimunised infants: a randomized controlled trial. Eur J Pediatr. 2020;179(6):297–316. doi:10.1007/s00431-020-03578-8
    1. Koelewijn JM, Slootweg YM, Folman C, van Kamp IL, Oepkes D, de Haas M. Diagnostic value of laboratory monitoring to predict severe hemolytic disease of the fetus and newborn in non‐D and non‐K‐alloimmunized pregnancies. Transfusion. 2020;60(2):391–399. doi:10.1111/trf.15631
    1. Slootweg YM, Lindenburg IT, Koelewijn JM, Van Kamp IL, Oepkes D, De Haas M. Predicting anti-kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management. Am J Obstet Gynecol. 2018;219(4):393–e1. doi:10.1016/j.ajog.2018.07.020
    1. Leafy MS, Ellarby NS. Early intravenous immunoglobulin. Eur J Pediatr. 2020;170(4):461–467. doi:10.1007/s00431-010-1310-8.Epub.2019
    1. Elalfy MS. Prevention of hemolytic disease of newborn. Eur J Pediatr. 2018;170(4):461–467. doi:10.1007/s00431-010-1310-8
    1. Osonoi K, Kudo K, Kobayashi A, et al. A comprehensive evaluation including ultrasound monitoring of fetal hemolytic disease in Rhesus E incompatibility. Hirosaki Med J. 2020;71(1):71–74.
    1. Agrawal A, Hussain KS, Kumar A. Minor blood group incompatibility due to blood groups other than Rh (D) leading to hemolytic disease of the fetus and newborn: a need for routine antibody screening during pregnancy. Intractable Rare Dis Res. 2020;60:1094–2019.
    1. Santavy J. Hemolytic disease in the newborn–history and prevention in the World and the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010;154(2):147–151. doi:10.5507/bp.2010.022
    1. Peyrard T, Pham BN, Arnaud L, et al. Fatal hemolytic disease of the fetus and newborn associated with anti‐Jra. Transfusion. 2008;48(9):1906–1911. doi:10.1111/j.1537-2995.2008.01787.x
    1. Noronha SA. Acquired and congenital hemolytic anemia. Pediatr Rev. 2016;37(6):235–246. doi:10.1542/pir.2015-0053
    1. Perinatal J. Intravenous Immunoglobulin G in treating ABO hemolytic disease of the newborn. Indian J Hematol Blood Transfus. 2021;132(3):e145–e232. doi:10.2342/peds.114.2.e143
    1. Crowe EP, Goel R. Survey of newborn direct antiglobulin testing practice in US and Canadian transfusion services. Transfusion. 2021;120(1):27–32. doi:10.1542/peds.2006-2910
    1. Wang N, Zhang L. A case of severe hemolytic disease of the newborn. N Engl J Med. 2021;37(1):1775–1777. doi:10.1056/NEJM199812103392410
    1. Maisonneuve E, Dugas A, Friszer S, et al. Effect of intravenous immunoglobulins to postpone the gestational age of first intrauterine transfusion in very severe red blood cell alloimmunization: a case-control study. J Gynecol Obstet Human Reprod. 2021;50(7):102119. doi:10.1016/j.jogoh.2021.102119
    1. Bussel JB, Vander Haar EL, Berkowitz RL. New developments in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol. 2021;225:120–127. doi:10.1016/j.ajog.2021.04.211
    1. Pegoraro V, Urbinati D, Visser GH, et al. Hemolytic disease of the fetus and newborn due to Rh (D) incompatibility: a preventable disease still produces significant morbidity and mortality in children. PLoS One. 2020;15(7):e0235807. doi:10.1371/journal.pone.0235807
    1. Bujandric N, Grujic J. Exchange transfusion for severe neonatal hyperbilirubinemia: 17 years experience from Vojvodina, Serbia. Indian J Hematol Blood Transfus. 2016;32(2):208–214. doi:10.1007/s12288-015-0534-1
    1. Hendrickson JE, Delaney M. Hemolytic disease of the fetus and newborn: modern practice and future investigations. Transfus Med Rev. 2016;30(4):159–164. doi:10.1016/j.tmrv.2016.05.008
    1. Delaney M, Matthews DC. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology. 2015;2015(1):146–151. doi:10.1182/asheducation-2015.1.146
    1. Mitra S, Rennie J. Neonatal jaundice: etiology, diagnosis, and treatment. Br J Hosp Med. 2017;78(12):699–704. doi:10.12968/hmed.2017.78.12.699
    1. Fasano RM. Hemolytic disease of the fetus and newborn in the molecular era. Semin Fetal Neonatal Med. 2016;21(1):28–34. doi:10.1016/j.siny.2015.10.006
    1. Quraishy N, Sapatnekar S. Advances in blood typing. Adv Clin Chem. 2016;77:221–269.
    1. Chen DP, Wen YH, Lu JJ, Tseng CP, Wang WT. Rapid rare ABO blood typing using a single PCR based on a multiplex SNaPshot reaction. J Formosan Med Assoc. 2019;118(1):395–400. doi:10.1016/j.jfma.2018.06.014
    1. Zhou ZZ, Xu D, Sun L, Lan J. The progress in pre-transfusion test technique research. Asia Pac J Blood Types Genes. 2017;1:7–12.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever